Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

P-023

Supelco

Phentermine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H15N
Numéro CAS:
122-09-8
Poids moléculaire :
149.23
Numéro MDL:
MFCD00059195
Code UNSPSC :
41116107
ID de substance PubChem :
329820023
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

2-8°C

Chaîne SMILES 

NC(C)(C)CC1=CC=CC=C1

InChI

1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

Clé InChI

DHHVAGZRUROJKS-UHFFFAOYSA-N

Catégories apparentées

Description générale

A Snap-N-Spike® reference solution applicable for use in clinical toxicology or urine drug testing by LC-MS/MS or GC/MS. Phentermine, a phenethylamine analog, is a stimulant and an appetite suppressant. This drug is a constituent of the withdrawn anti-obesity medication fen-phen.

Application

  • Phentermine solution for weight loss research: Phentermine is extensively studied as an appetite suppressant in obesity treatment. Its effectiveness in weight loss regimens is often analyzed through pharmaceutical research, where the solution form facilitates precise dosing and control in clinical trials, enhancing the understanding of its pharmacodynamics and therapeutic potential (Ni et al., 2015).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Pentobarbital solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-010

Pentobarbital solution

Fiona Cameron et al.
Drugs, 72(15), 2033-2042 (2012-10-09)
Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed
Prescrire international, 22(136), 61-64 (2013-04-18)
The cornerstones of treatment for obesity, and even more so for simple overweight, are dietary measures and physical exercise. There are no drugs with a favourable harm-benefit balance in this setting. A fixed-dose combination of topiramate, an antiepileptic drug, and
Two new drugs approved for obesity.
Annette M Johnson
South Dakota medicine : the journal of the South Dakota State Medical Association, 65(9), 356-357 (2012-10-17)
Eva Manakova et al.
Neuro endocrinology letters, 33 Suppl 3, 179-182 (2013-01-29)
Both, obesity as well as anorexia may be associated with infertility and other complications of pregnancy. Weight loss during pregnancy is therefore considered a risk factor. Weight loss and appetite suppressant are contraindicated during pregnancy, but the unintended exposure is
New medications for weight loss.
Melissa Murfin
JAAPA : official journal of the American Academy of Physician Assistants, 25(12), 59-60 (2013-04-23)
Afficher tous les articles scientifiques apparentés

Protocoles

US EPA Method 8270 (Appendix IX): GC Analysis of Semivolatiles on Equity®-5 (30 m x 0.25 mm I.D., 0.50 μm)

US EPA Method 8270 (Appendix IX): GC Analysis of Semivolatiles on Equity®-5 (30 m x 0.25 mm I.D., 0.50 μm)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique